Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why - MarketWatch
Wall Street is buzzing about Gilead’s rheumatoid arthritis drug. Here’s why MarketWatch
Shares of Belgium-based biotech Galapagos NV soared 23% on Friday after the company, together with pharmaceutical giant Gilead Sciences Inc., announced.
Comments
Post a Comment